Stockscreener 앱 받기
1.1001
6.19%
0.0501
전일 마감가:
$1.05
열려 있는:
$1.07
하루 거래량:
83,922
Relative Volume:
0.54
시가총액:
$62.27M
수익:
-
순이익/손실:
$-131.52M
주가수익비율:
-0.618
EPS:
-1.78
순현금흐름:
$-107.56M
1주 성능:
+17.99%
1개월 성능:
+32.41%
6개월 성능:
+28.03%
1년 성능:
-79.20%
1일 변동 폭
$1.07
$1.14
1주일 범위
$0.8221
$1.14
52주 변동 폭
$0.6101
$5.945
Prelude Therapeutics Inc Stock (PRLD) Company Profile
명칭
Prelude Therapeutics Inc
전화
(302) 467-1280
주소
175 INNOVATION BOULEVARD, WILMINGTON
PRLD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
1.1001 | 53.44M | 0 | -131.52M | -107.56M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.69 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
592.13 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.87 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.05 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
311.64 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-19 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-06-20 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2024-03-13 | 개시 | JMP Securities | Mkt Outperform |
| 2024-02-20 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-12-19 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2022-11-21 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-09-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-29 | 개시 | Jefferies | Buy |
| 2022-03-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-02-28 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-10-08 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-07-27 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-04-26 | 개시 | H.C. Wainwright | Buy |
| 2021-03-09 | 개시 | Barclays | Overweight |
| 2020-11-20 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-10-20 | 개시 | BofA Securities | Buy |
| 2020-10-20 | 개시 | Goldman | Neutral |
| 2020-10-20 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Prelude Therapeutics Inc 주식(PRLD)의 최신 뉴스
What makes Prelude Therapeutics Incorporated stock price move sharplyJuly 2025 Volume & Free Community Supported Trade Ideas - Newser
Price momentum metrics for Prelude Therapeutics Incorporated explainedJuly 2025 PostEarnings & Consistent Profit Focused Trading Strategies - Newser
Can swing trading help recover from Prelude Therapeutics Incorporated losses2025 Pullback Review & Pattern Based Trade Signal System - Newser
Quantitative breakdown of Prelude Therapeutics Incorporated recent moveMarket Risk Summary & Long-Term Capital Growth Ideas - Newser
Is now a turning point for Prelude Therapeutics IncorporatedEarnings Recap Summary & AI Enhanced Trading Alerts - Newser
Analyzing drawdowns of Prelude Therapeutics Incorporated with statistical tools2025 Technical Overview & Growth Focused Stock Reports - Newser
Prelude Therapeutics Incorporated recovery potential after sell off2025 Breakouts & Breakdowns & Technical Confirmation Alerts - Newser
Chart overlay techniques for tracking Prelude Therapeutics IncorporatedJuly 2025 Earnings & Long Hold Capital Preservation Tips - Newser
Prelude Therapeutics (NASDAQ:PRLD) Given New $3.00 Price Target at JMP Securities - Defense World
Tick level data insight on Prelude Therapeutics Incorporated volatilityWeekly Trade Analysis & Weekly High Conviction Ideas - Newser
Prelude Therapeutics (NASDAQ:PRLD) Trading Up 8.5% – Here’s What Happened - Defense World
Prelude Therapeutics price target lowered to $3 from $4 at Citizens JMP - TipRanks
Will Prelude Therapeutics Incorporated stock go up soon2025 Dividend Review & Community Consensus Trade Alerts - Newser
Has Prelude Therapeutics Incorporated found a price floor2025 AllTime Highs & Safe Entry Point Alerts - Newser
Risk vs reward if holding onto Prelude Therapeutics IncorporatedTrade Exit Summary & Daily Growth Stock Tips - Newser
How to build a dashboard for Prelude Therapeutics Incorporated stockJuly 2025 Market Mood & Target Return Focused Picks - Newser
Prelude Therapeutics Refocuses SMARCA2 Program, Cuts Quarterly Losses - MyChesCo
Best data tools to analyze Prelude Therapeutics Incorporated stockMarket Performance Summary & Advanced Technical Analysis Signals - Newser
Will Prelude Therapeutics Incorporated bounce back from current supportQuarterly Earnings Summary & Weekly Watchlist for Hot Stocks - Newser
Is Prelude Therapeutics Incorporated reversing from oversold territoryNew Guidance & Free Technical Pattern Based Buy Signals - Newser
Does Prelude Therapeutics Incorporated qualify in momentum factor screening2025 Valuation Update & Advanced Technical Analysis Signals - Newser
Is it time to cut losses on Prelude Therapeutics IncorporatedJuly 2025 Volume & AI Driven Price Forecasts - Newser
Prelude Therapeutics Incorporated stock trendline breakdown2025 Winners & Losers & Comprehensive Market Scan Insights - Newser
Why Prelude Therapeutics Incorporated stock attracts strong analyst attentionQuarterly Profit Report & Real-Time Volume Analysis Alerts - Newser
Is Prelude Therapeutics Incorporated trading at a discountTrade Risk Summary & Community Verified Trade Signals - thegnnews.com
Neurizon cites ‘strain’ at FDA as reason for delay on IND hold; Fifty Years’ $126M fund - Endpoints News
Prelude Therapeutics Reports Q2 2025 Financial Results - TipRanks
Prelude Therapeutics Pauses Intravenous SMARCA2 Degrader Development - TipRanks
Prelude Cuts Q2 Losses and Costs 13% - The Motley Fool
Prelude (PRLD) Announces Q2 2025 Results; Presentation Attached | PRLD SEC FilingForm 8-K - Stock Titan
Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Yahoo Finance
Prelude Therapeutics Inc (PRLD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Prelude Therapeutics Inc 주식 (PRLD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Vaddi Krishna | CEO |
Mar 25 '25 |
Buy |
0.69 |
675,000 |
467,438 |
1,999,296 |
| Vaddi Krishna | CEO |
Mar 21 '25 |
Buy |
0.73 |
15,000 |
10,959 |
1,324,296 |
| Vaddi Krishna | CEO |
Mar 20 '25 |
Buy |
0.73 |
5,416 |
3,950 |
1,309,296 |
| Vaddi Krishna | CEO |
Mar 14 '25 |
Buy |
0.75 |
29,999 |
22,631 |
1,294,774 |
| Vaddi Krishna | CEO |
Mar 17 '25 |
Buy |
0.75 |
9,106 |
6,829 |
1,303,880 |
| Vaddi Krishna | CEO |
Mar 13 '25 |
Buy |
0.72 |
50,000 |
35,820 |
1,264,775 |
| Vaddi Krishna | CEO |
Mar 12 '25 |
Buy |
0.71 |
47,500 |
33,744 |
1,214,775 |
| Vaddi Krishna | CEO |
Dec 31 '24 |
Buy |
1.21 |
5,000 |
6,044 |
142,553 |
| Vaddi Krishna | CEO |
Dec 30 '24 |
Buy |
1.20 |
10,000 |
12,000 |
137,553 |
| Combs Andrew | Chief Chemistry Officer |
Dec 23 '24 |
Buy |
1.37 |
60,000 |
82,002 |
377,623 |
0.41%
0.00%
자본화:
|
볼륨(24시간):